Multivariate analyses of cytogenetic risk groups after unrelated donor transplantation for AML in first complete remission
| Outcome . | No. . | Relative risk (95% CI) . | P . |
|---|---|---|---|
| Treatment-related mortality* | |||
| Intermediate | 155 | 1.00‖ | |
| Unfavorable | 82 | 0.91 (0.62-1.35) | .65 |
| Relapse† | |||
| Intermediate | 155 | 1.00‖ | |
| Unfavorable | 82 | 2.22 (1.22-4.06) | .009 |
| Treatment failure‡ | |||
| Intermediate | 155 | 1.00‖ | |
| Unfavorable | 82 | 1.23 (0.89-1.70) | .21 |
| Death§ | |||
| Intermediate | 155 | 1.00‖ | |
| Unfavorable | 82 | 1.14 (0.82-1.59) | .43 |
| Outcome . | No. . | Relative risk (95% CI) . | P . |
|---|---|---|---|
| Treatment-related mortality* | |||
| Intermediate | 155 | 1.00‖ | |
| Unfavorable | 82 | 0.91 (0.62-1.35) | .65 |
| Relapse† | |||
| Intermediate | 155 | 1.00‖ | |
| Unfavorable | 82 | 2.22 (1.22-4.06) | .009 |
| Treatment failure‡ | |||
| Intermediate | 155 | 1.00‖ | |
| Unfavorable | 82 | 1.23 (0.89-1.70) | .21 |
| Death§ | |||
| Intermediate | 155 | 1.00‖ | |
| Unfavorable | 82 | 1.14 (0.82-1.59) | .43 |
CI indicates confidence interval.
Other significant covariates were recipient CMV status (positive vs negative: RR = 1.71, 95% CI, 1.16–2.53, P = .007); cell dose (Poverall2 < 0.001; ≤ 3 × 108/kg vs > 3 × 108/kg within first 6 months after transplantation: RR = 2.99, 95% CI, 1.73-5.18, P < .001; cell dose ≤ 3 × 108/kg vs > 3 × 108/kg beyond first 6 months after transplantation: RR = 0.78, 95% CI, 0.36-1.72, P = 0.54) and time from diagnosis to transplant (>6 months vs <6 months: RR = 1.58, 95% CI = 1.09-2.29, P = .016).
Other significant covariates were donor-recipient HLA match (mismatch vs match: RR = 4.41, 95% CI = 2.27-8.59, P < .001), time from diagnosis to transplantation (> 6 months vs ≤ 6 months: RR = .45, 95% CI = 0.23-0.86, P = .015) and GVHD prophylaxis (Poverall2 = 0.030; FK506 ± other vs CSA + MTX ± other: RR = 0.57, 95% CI = 0.25-1.32, P = .19; T-cell depletion vs CSA + MTX ± other: RR = 0.39, 95% CI = 0.19-0.82, P = .013; T-cell depletion vs FK506 ± other: RR = 0.68, 95% CI = 0.25-1.89, P = .46).
Other significant covariates were cell dose (Poverall2 = 0.029; ≤ 3 × 108/kg vs > 3 × 108/kg within first 6 months after transplantation: RR = 1.74, 95% CI = 1.14-2.66, P = .010; cell dose ≤ 3 × 108/kg vs > 3 × 108/kg beyond first 6 months after transplant: RR = 0.82, 95% CI = 0.46-1.44, P = 0.49) and donor-recipient HLA match (Poverall2 < 0.001; mismatch vs match within first 3 months after transplantation: RR = 1.03, 95% CI = 0.61-1.72, P = 0.92; mismatch vs match beyond first 3 months after transplantation: RR = 2.51, 95% CI = 1.60-3.94, P < .001).
Other significant covariates were cell dose (Poverall2<0.001; ≤ 3 × 108/kg vs > 3 × 108/kg within first 6 months after transplantation: RR = 2.53, 95% CI = 1.56-4.08, P < .001; cell dose ≤ 3 × 108/kg vs > 3 × 108/kg beyond first 6 months after transplantation: RR = 0.68, 95% CI = 0.40-1.15, P = .15) and donor-recipient HLA match (Poverall2 = 0.001; mismatch vs match within first 3 months after transplantation: RR = 0.94, 95% CI = 0.56-1.60, P = .83; mismatch vs match beyond first 3 months after transplantation: RR = 2.31, 95% CI = 1.48-3.59, P < .001).
Reference group.